Dermatology News and Research

Latest Dermatology News and Research

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.

20 Oct 2010

Many skin cancer patients unaware of being diagnosed with melanoma or nonmelanoma cancer

Socioeconomic factors such as a lower level of education and lack of health insurance may impact individuals' knowledge of the type of skin cancer with which they are diagnosed. As a result, these individuals may have a poor sense of the measures they need to take to reduce the risk of future skin cancers.

19 Oct 2010

Discovery of 4 new DNA 'hotspots' may aid in developing new therapies for psoriasis

Scientists at the University of Michigan Heath System and their collaborators have found four new DNA "hotspots" that may one day help guide new treatments for psoriasis, one of the most common autoimmune diseases in the country.

19 Oct 2010

PCE, NPF form partnership to provide education programs on psoriasis

Practicing Clinicians Exchange (PCE) has formed a partnership with the National Psoriasis Foundation (NPF) to provide continuing education programs to nurse practitioners (NPs) and physician assistants (PAs) throughout the United States.

19 Oct 2010

JPO issues patent grant for Apricus's Femprox

Apricus Biosciences, Inc., backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Japanese Patent Office has issued a Decision to Grant a Patent for the Company's application on Femprox entitled, Compositions and Methods for Amelioration of Human Female Sexual Dysfunction.

19 Oct 2010

Elorac acquires world-wide rights to Cidoxepin

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, is pleased to announce that it has acquired world-wide rights to the active agent Cidoxepin from Gideon Pharmaceuticals. Cidoxepin is the cis-isomer of the widely prescribed tricyclic compound doxepin.

19 Oct 2010

Discovery may aid in developing new psoriasis therapies

Scientists at the University of Michigan Heath System and their collaborators have found four new DNA “hotspots” that may one day help guide new treatments for psoriasis, one of the most common autoimmune diseases in the country.

18 Oct 2010

Emollient creams on eczemous skin likely to make condition worse

New research at the University of Bath suggests that using emollient creams to relieve the symptoms of eczema could actually make the condition worse.

18 Oct 2010

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.

18 Oct 2010

Moores Cancer Center files IND application for topical NexACT-based formulation

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).

15 Oct 2010

Coalition for At-Risk Youth helps foster children improve self-esteem

There is no denying that teenagers in the foster care system need special support so they can begin to develop the skills that will take them successfully into adulthood. Those with skin, hair or nail diseases may face even more challenges because their self-esteem may have been shattered by the obvious signs of their condition.

14 Oct 2010

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a focusing of its resources on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and supporting strategic alliances with Roche and Baxter such as validation of Halozyme's commercial scale manufacturing process to produce kilogram quantities of enzyme.

12 Oct 2010

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with etanercept (Enbrel®), methotrexate or placebo. Abbott presented data from all briakinumab pivotal studies in psoriasis at the European Association of Dermatology and Venereology scientific sessions.

11 Oct 2010

IRIDEX introduces new family of Adjustable & Intuitive EndoProbe laser handpieces

IRIDEX Corporation today announced commercial availability of a new family of Adjustable & Intuitive EndoProbe laser handpieces for use with the Company's laser platforms in vitreoretinal surgery.

11 Oct 2010

FDA approves Warner Chilcott's ACTONEL for postmenopausal osteoporosis

Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its next generation ACTONEL® (risedronate sodium) product for the treatment of postmenopausal osteoporosis in the United States. The product will be marketed as ATELVIA™ (risedronate sodium) delayed-release tablets.

11 Oct 2010

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Progress in understanding mechanism behind photocontact allergy

What happens to sunscreens when they are exposed to sunlight? And how is the skin affected by the degradation products that form? This has been the subject of research at the University of Gothenburg and Chalmers University of Technology that will be presented at the upcoming dermatologist conference in Gothenburg.

11 Oct 2010

Research reveals that fragrances can cause contact allergy

The fragrances used in many household and skincare products can cause contact allergy when exposed to oxygen in the air, reveals research from the University of Gothenburg's Faculty of Science in conjunction with the University of Gothenburg to be presented at the dermatologist conference in Gothenburg.

11 Oct 2010

Suneva Medical publishes Artefill data for treatment of atrophic acne scars

Suneva Medical, a privately-held aesthetic medical device company, today announced the publication of an open-label, single center, pilot study on Artefill for the treatment of atrophic acne scars conducted by James M. Spencer, M.D. M.S. and sponsored by Suneva Medical.

8 Oct 2010

ABMS awarded HHS contract to align meaningful use of HIT, ABMS MOC program

The American Board of Medical Specialties announced today a contract from the U.S. Department of Health and Human Services to align the meaningful use of health information technology and the ABMS Maintenance of Certification program, which was created by ABMS and its 24 Member Boards to promote lifelong learning and self assessment for physician specialists. The contract was awarded by the HHS Office of the National Coordinator for HIT.

8 Oct 2010